fusion protein

SNAP-fusion protein ligand-1 (Compound 1i) serves as a ligand for a target protein in PROTAC (Ligand for Target Protein for PROTAC) applications. It is used in the synthesis of PROTAC VHL-SNAP2-5C.

Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.

Shield-1 is a specific, high-affinity, and cell-permeable ligand for FK506-binding protein 12 (FKBP) and reverses instability by binding to mutant FKBP (mtFKBP), allowing conditional expression of mtFKBP fusion proteins.

Alefacept (BG 9273), a fusion protein combining human lymphocyte function-associated antigen 3 with immunoglobulin 1, is utilized in the research of chronic plaque psoriasis [1].

Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

Olamkicept (FE-301) is a soluble gp130-Fc-fusion protein that selectively inhibits interleukin 6 (IL-6) trans-signaling by binding to the soluble IL-6 receptor/IL-6 complex.

Abatacept is a soluble recombinant fusion protein consisting of the extracellular domain of human CTLA-4 and the Fc portion of human IgG1. It binds with high affinity to CD80 and CD86 on antigen-presenting cells, specifically blocking the CD28-mediated costimulatory signal required for T-cell activation. Abatacept is widely used to investigate rheumatoid arthritis, autoimmune responses, and immune dysregulation caused by LRBA deficiency.

AP20187 (B/B Homodimerizer) is a cell-permeable compound used to dimerize FK506-binding protein (FKBP) fusion proteins, thereby initiating biological signaling cascades, gene expression, or disrupting protein-protein interactions.

Enzomenib is a menin protein inhibitor that disrupts the interaction between menin and mixed lineage leukemia fusion proteins, thereby modulating transcriptional programs driven by MEN gene dysregulation and providing a targeted research tool for mechanistic studies and therapeutic exploration in hematological malignancies associated with menin-dependent oncogenic signaling.

PROTAC ALK degrader-3 (4B) is an orally active PROTAC-based ALK degrader, efficiently inducing sustained degradation of ALK fusion protein and significant inhibition of downstream pathways in Karpas 299 cells with an IC50 of 119.33 nM. This compound exhibits antitumor activity.

UR-AK49 (compound 11) is an agonist for the human histamine H1 and H2 receptors. It exhibits an EC50 of 23 nM in the GTPase assay involving hH2R-Gsalpha fusion protein expressed in Sf9 insect cells. UR-AK49 is applicable in neurologically related research.

CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV.

GNF-2-deg is a PROTAC degrader that targets the envelope protein of the dengue virus (DENV E protein), achieving a DC50 of 0.83 μM. It inhibits viral entry by preventing membrane fusion mediated by the E protein and demonstrates antiviral activity against DENV 2 through protein degradation, with an EC90 of 3.5 μM. Additionally, GNF-2-deg shows antiviral efficacy against ZIKV, JEV, WNV, and YFV, with EC90 values ranging from 1.96 to 7.79 μM.

RUNX1/ETO-IN-1 is an inhibitor targeting the oncogenic fusion protein RUNX1-ETO, specifically affecting the NHR2 oligomerization domain. It binds directly to NHR2 (KD,app = 39 μM). By inducing apoptosis and promoting differentiation, RUNX1/ETO-IN-1 exhibits antileukemic activity in RUNX1/ETO translocation acute myeloid leukemia (AML) cells. Its near-neutral charge under physiological pH conditions grants it excellent cell membrane permeability.

CC-647 is a molecular glue modulator targeting the Cereblon (CRBN) E3 ubiquitin ligase. It enhances the interaction between CRBN and ZBTB16, as well as its oncogenic fusion protein RARα-ZBTB16, with a half-maximal degradation concentration (DC50) of 103 nM for ZBTB16. CC-647 holds potential for studying ZBTB16-RARα related acute promyelocytic leukemia (APL).

VHL-SNAP2-5C is a PROTAC degrader based on the self-labeling protein SNAP tag. It enables visualization and selective removal of SNAP-fusion proteins, such as CLCa and EGFP, when endogenously labeled.

PROTACBET Degrader-13 (Compound 34) is a TRIM21-based PROTAC (TRIMTAC) degrader that targets BET proteins. It effectively degrades the PML-eGFP-BRD4 fusion protein, causing a near-complete loss of EGFP+ nuclear foci with an EC50 of 1.4 μM.

Glycoprotein B is a peptide with the sequence H2N-Ser-Ser-Ile-Glu-Phe-Ala-Arg-Leu-OH, MW= 922.04. glycoprotein B is a viral glycoprotein that is involved in the viral cell entry of Herpes simplex virus. The herpesvirus glycoprotein B is the most highly c

RV521 is a highly effective fusion inhibitor. It designed to treat RSV disease by the target of a surface protein that mediates RSV binding to cellular receptors.

JNJ-2408068 is an inhibitor of respiratory syncytial virus (RSV). JNJ-2408068 exhibited potent antiviral activity with EC50 of 2.1 nM. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50= 0.9 nM). JNJ-2408068 interferes with

SLUPP-225 is an efflux pump inhibitor (EPI) by interacting with the membrane fusion protein AcrA, a critical component of the AcrAB-TolC efflux pump in Escherichia coli.

SLUPP-417 is an efflux pump inhibitor (EPI) by interacting with the membrane fusion protein AcrA, a critical component of the AcrAB-TolC efflux pump in Escherichia coli.

Degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide . Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.27 nM; Dmax = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications. Mouse DMPK properties are provided in the supplementary file (see below). (MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in - see protocol for more information.) 0

Degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide . Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.34 nM; Dmax = 93.14%). Cell-permeable. Suitable for in vitro and in vivo applications. Mouse DMPK properties are provided in the supplementary file (see below). (MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in - see protocol for more information.) 0